NYSE:NVS Novartis (NVS) Stock Price, News & Analysis $116.65 +0.16 (+0.14%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$116.62▼$117.6050-Day Range$106.13▼$120.8952-Week Range$92.19▼$120.92Volume1.15 million shsAverage Volume880,725 shsMarket Capitalization$238.43 billionP/E Ratio15.74Dividend Yield2.08%Price Target$118.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Novartis alerts: Email Address Novartis MarketRank™ Stock AnalysisAnalyst RatingReduce1.86 Rating ScoreUpside/Downside1.5% Upside$118.38 Price TargetShort InterestBearish0.30% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainabilityN/ANews Sentiment0.59Based on 28 Articles This WeekInsider TradingN/AProj. Earnings Growth10.83%From $7.48 to $8.29 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.98 out of 5 starsMedical Sector777th out of 910 stocksPharmaceutical Preparations Industry362nd out of 426 stocks 0.9 Analyst's Opinion Consensus RatingNovartis has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst CoverageNovartis has only been the subject of 4 research reports in the past 90 days.Read more about Novartis' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.30% of the float of Novartis has been sold short.Short Interest Ratio / Days to CoverNovartis has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Novartis has recently increased by 4.63%, indicating that investor sentiment is decreasing. Previous Next 2.5 Dividend Strength Dividend YieldNovartis pays a meaningful dividend of 2.01%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthNovartis does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Novartis is 32.79%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Novartis will have a dividend payout ratio of 29.31% next year. This indicates that Novartis will be able to sustain or increase its dividend.Read more about Novartis' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVS. Previous Next 2.5 News and Social Media Coverage News SentimentNovartis has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 28 news articles for Novartis this week, compared to 11 articles on an average week.Search Interest7 people have searched for NVS on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Novartis to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Novartis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.01% of the stock of Novartis is held by insiders.Percentage Held by InstitutionsOnly 13.12% of the stock of Novartis is held by institutions.Read more about Novartis' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Novartis are expected to grow by 10.83% in the coming year, from $7.48 to $8.29 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novartis is 15.74, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.08.Price to Earnings Ratio vs. SectorThe P/E ratio of Novartis is 15.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.96.Price to Earnings Growth RatioNovartis has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioNovartis has a P/B Ratio of 5.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Novartis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Novartis Stock (NYSE:NVS)Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Read More NVS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVS Stock News HeadlinesSeptember 6 at 7:28 PM | markets.businessinsider.comNovartis: A Hold Rating with Modest Upside Amid Strong Product Performance and Promising PipelineSeptember 6 at 4:59 AM | americanbankingnews.comNovartis (NYSE:NVS) Receives "Neutral" Rating from The Goldman Sachs GroupSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 6 at 2:03 AM | americanbankingnews.comNovartis AG to Post Q2 2025 Earnings of $2.07 Per Share, Zacks Research Forecasts (NYSE:NVS)September 5 at 2:36 PM | baystreet.caVoyager Vaults on Novartis LinkSeptember 5 at 9:35 AM | markets.businessinsider.comNovartis Granted License For Novel Capsid Generated From Voyager's TRACER Capsid Discovery PlatformSeptember 5 at 4:34 AM | seekingalpha.comNovartis expands U.S. radiopharma production amid rising competitionSeptember 5 at 4:34 AM | investing.comMorgan Stanley cuts Novartis rating amid limited innovationSeptember 7, 2024 | Weiss Ratings (Ad)“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.September 4 at 6:01 AM | americanbankingnews.comZacks Research Comments on Novartis AG's FY2024 Earnings (NYSE:NVS)September 4 at 3:05 AM | americanbankingnews.comNovartis (NYSE:NVS) Downgraded by Jefferies Financial Group to HoldSeptember 3, 2024 | msn.comIs Novartis AG (NVS) the Best Cancer Stock to Buy Now?September 3, 2024 | msn.comJefferies downgrades Novartis despite long-term optimismAugust 30, 2024 | lse.co.ukNovartis Ag Share Price (NVS.US)August 29, 2024 | markets.businessinsider.comLindy Biosciences Inks Multi-target Licensing Agreement And Collaboration With Novartis PharmaAugust 29, 2024 | msn.comNovartis' Cholesterol-Lowering Drug Shows Encouraging Outcome In Late-Stage StudyAugust 29, 2024 | bizjournals.comNovartis deal could net Triangle firm nearly $1 billionAugust 29, 2024 | msn.comChart of the Day: Novartis - Take Another LookSee More Headlines Receive NVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/18/2024Today9/07/2024Next Earnings (Confirmed)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:NVS CUSIPN/A CIK1114448 Webwww.novartis.com Phone(161) 324-1111Fax41-61-324-7826Employees76,057Year Founded1996Price Target and Rating Average Stock Price Target$118.38 High Stock Price Target$122.50 Low Stock Price Target$114.00 Potential Upside/Downside+1.5%Consensus RatingReduce Rating Score (0-4)1.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$7.41 Trailing P/E Ratio15.74 Forward P/E Ratio15.59 P/E Growth1.77Net Income$14.85 billion Net Margins33.76% Pretax Margin22.75% Return on Equity34.56% Return on Assets14.24% Debt Debt-to-Equity Ratio0.47 Current Ratio0.93 Quick Ratio0.72 Sales & Book Value Annual Sales$45.44 billion Price / Sales5.25 Cash Flow$10.72 per share Price / Cash Flow10.88 Book Value$22.87 per share Price / Book5.10Miscellaneous Outstanding Shares2,044,000,000Free Float2,043,796,000Market Cap$238.43 billion OptionableOptionable Beta0.57 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Vasant Narasimhan M.D. (Age 48)Chief Executive Officer Comp: $8.01MMr. Harry Kirsch (Age 59)Chief Financial Officer Comp: $3.99MMr. Victor Bulto (Age 46)President of US Comp: $3.28MDr. Patrick Horber M.D. (Age 54)President of International Comp: $7.31MDr. Steffen Lang Ph.D. (Age 57)President of Operations Comp: $2.34MPaul PenepentHead of Group Financial Reporting and AccountingMs. Sloan SimpsonGlobal Head of Investor RelationsDr. Klaus Moosmayer Ph.D. (Age 56)Chief Ethics, Risk & Compliance Officer Comp: $1.55MMs. Karen L. Hale (Age 56)Chief Legal Officer Comp: $2.34MDr. Robert Kowalski Pharm.D. (Age 56)Chief People & Organization Officer Comp: $2.1MMore ExecutivesKey CompetitorsNovo Nordisk A/SNYSE:NVOAstraZenecaNASDAQ:AZNSanofiNASDAQ:SNYGSKNYSE:GSKTakeda PharmaceuticalNYSE:TAKView All CompetitorsInstitutional OwnershipSanctuary Advisors LLCBought 81,158 shares on 9/5/2024Ownership: 0.004%Centennial Bank AR Sold 107 shares on 8/30/2024Ownership: 0.000%Teachers Retirement System of The State of KentuckyBought 57,000 shares on 8/26/2024Ownership: 0.011%Delphi Management Inc. MABought 403 shares on 8/26/2024Ownership: 0.001%Cetera Investment AdvisersBought 3,121 shares on 8/22/2024Ownership: 0.005%View All Institutional Transactions Should I Buy Novartis Stock? NVS Pros and Cons Explained Pros Here are some ways that investors could benefit from investing in Novartis AG: Novartis AG has recently launched a groundbreaking new drug that is expected to significantly boost revenue and profits. The company's stock price has been steadily increasing over the past year, indicating positive investor sentiment. Novartis AG has a strong pipeline of innovative products in development, which could drive future growth. Recent acquisitions by Novartis AG have expanded its market reach and diversified its product portfolio. Novartis AG has a solid financial position with healthy cash reserves and low debt levels, providing stability and flexibility for future investments. Cons Investors should be bearish about investing in Novartis AG for these reasons: There is potential regulatory risk associated with the pharmaceutical industry, which could impact Novartis AG's operations and profitability. Competition in the healthcare sector is intense, and Novartis AG may face challenges in maintaining market share and pricing power. Global economic uncertainties and geopolitical tensions could affect Novartis AG's international operations and revenue streams. The healthcare sector is subject to rapid technological advancements and changing consumer preferences, posing risks of product obsolescence for Novartis AG. Fluctuations in currency exchange rates could impact Novartis AG's financial performance, especially in markets with high volatility. These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, August 18, 2024. Please send any questions or comments about these Novartis pros and cons to contact@marketbeat.com. NVS Stock Analysis - Frequently Asked Questions How have NVS shares performed this year? Novartis' stock was trading at $100.97 at the beginning of 2024. Since then, NVS shares have increased by 15.5% and is now trading at $116.65. View the best growth stocks for 2024 here. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) announced its quarterly earnings results on Thursday, July, 18th. The company reported $1.97 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.87 by $0.10. The firm earned $12.87 billion during the quarter, compared to analysts' expectations of $12.24 billion. Novartis had a net margin of 33.76% and a trailing twelve-month return on equity of 34.56%. What is Vas Narasimhan's approval rating as Novartis' CEO? 938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Novartis have any subsidiaries? The following companies are subsidiaries of Novartis: Gyroscope Therapeutics, Arctos Medical, Cellerys, Cadent Therapeutics, Vedere Bio, Vedere Bio ll, Amblyotech, and others. Who are Novartis' major shareholders? Top institutional shareholders of Novartis include Primecap Management Co. CA (0.60%), Dimensional Fund Advisors LP (0.36%), Renaissance Technologies LLC (0.12%) and Principal Financial Group Inc. (0.12%). How do I buy shares of Novartis? Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Novartis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS) and Gilead Sciences (GILD). This page (NYSE:NVS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
